Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Ulcerative colitis (UC)
Crohn’s disease (CD)
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Upcoming Conferences
Genentech will be present at the following upcoming conferences. Visit our medical booth for the latest information and connect with a Medical Science Liaison (MSL).
January 22-24, Las Vegas
Crohn's and Colitis Conference
February 19-21, Stockholm
European Crohn’s and Colitis Organization
May 2-5, Chicago
Digestive Disease Week
Pipeline
Genentech’s pipeline for inflammatory bowel diseases includes multiple molecules currently under investigation across two indications in adult and pediatric patient populations.
These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.
Afimkibart Proposed Mechanism of Action
Watch the video
Afimkibart is an investigational monoclonal antibody, targeting the TL1A protein, being evaluated as a potential treatment for inflammatory and fibrotic diseases.
Afimkibart and its uses are investigational and have not been approved by regulatory authorities worldwide. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
IBD Afimkibart Proposed MOA
Actively Recruiting Clinical Trials
| Afimkibart (RO7790121) | |||
|---|---|---|---|
| Indication | Phase | Trial Name | |
| Crohn’s disease | Phase III | A Phase III, Multicenter, Double-Blind Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart in Patients With Moderately to Severely Active Crohn’s Disease (Siberite-1) | Visit trial |
| Crohn’s disease | Phase III | A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Asses the Efficacy and Safety of Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Crohn’s Disease (Siberite-2) | Visit trial |
| Ulcerative colitis | Phase III | A Phase III, Multicenter, Double-Blind Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis (Ametrine-1) | Visit trial |
| Ulcerative colitis | Phase III | A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Asses the Efficacy and Safety of Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) | Visit trial |
| Ulcerative colitis | Phase III | A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart in Children Aged 2-17 Years With Moderately to Severely Active Ulcerative Colitis | Visit trial |
Interested in becoming an investigator or have trial questions?
Afimkibart IBD Congress Presentations
Select each item to view more information and view the material.
UEGW 2025 | Poster
Afimkibart (Anti-TL1A) Blocks Cellular Signaling Induced by Active TL1A
Fuh, F, Varfolomeev, E, Nguyen, A, et al.
UEGW 2025 | Poster
Baseline Characteristics Predicting afimkibart Remission/Benefit (TUSCANY-2)
Peyrin-Biroulet, L.
DDW 2025 | Presentation
Afimkibart: Evaluation of Histologic and Endoscopic Endpoints in UC
Jairath, V.
DDW 2025 | Poster
Afimkibart Shows Early/Rapid Symptomatic Remission in UC (TUSCANY-2)
Allegretti, J.
CCC 2025 | Poster
Afimkibart: Early Clinical Response/Symptom Improvement in UC (Phase 2b)
Allegretti, J.
UEGW 2024 | Presentation
Efficacy/Safety of afimkibart (Anti-TL1A) in UC: Phase 2b Results
Danese, S.
ACG 2024 | Presentation
TUSCANY-2 Phase 2b: Efficacy/Safety of afimkibart (Anti-TL1A) in Active UC
Danese, S.
AIBD 2024 | Poster
Efficacy & Quality of Life Results in UC (Phase 2b)
Yanur, A.
Publications
The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria.
To browse a full listing of published scientific literature: Visit PubMed
Stay updated
Follow us on Linkedin or X to receive the latest scientific updates from Genentech.
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT